Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript

Core Viewpoint - Rhythm Pharmaceuticals announced positive preliminary data from an exploratory Phase II trial of setmelanotide for Prader-Willi syndrome, indicating a potential efficacy signal [2]. Group 1: Company Overview - Rhythm Pharmaceuticals is conducting research on setmelanotide, which is being evaluated for its effectiveness in treating Prader-Willi syndrome [2][3]. - The company held a conference call to discuss the trial results, with key presentations from its leadership and external experts [1][3]. Group 2: Trial Details - The Phase II trial is exploratory in nature and aims to assess the efficacy of setmelanotide in patients with Prader-Willi syndrome [2][3]. - Dr. Jennifer Miller from the University of Florida is the principal investigator for this Phase II trial, highlighting the collaboration with academic institutions [3].